ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

The ICON Collaborators

The Lancet (British edition), 1998-11, Vol.352 (9140), p.1571-1576 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível